董事介绍

注:董事持股数取自最新公司公告

姓名 性别 职位 年龄 薪酬 持股数(万股) 截止日期
Candace H. Duncan Director 72 31.38万美元 1.73 2026-05-15
Neena M. Patil Director 51 31.72万美元 0.23 2026-05-15
Jaewon Ryu Director 52 未披露 未持股 2026-05-15
Stuart A. Randle Chief Executive Officer and Director and Interim President 67 28.33万美元 1.54 2026-05-15
Andrew A. Krakauer Director 71 27.04万美元 1.17 2026-05-15
Michael J. Tokich Director 57 未披露 未持股 2026-05-15
Gretchen R. Haggerty Director 70 28.73万美元 1.34 2026-05-15

高管介绍

注:高管持股数取自最新公司公告

姓名 性别 职位 年龄 薪酬 持股数(万股) 截止日期
Cameron P. Hicks Corporate Vice President, Human Resources and Communications 61 134.32万美元 未持股 2026-05-15
John R. Deren Executive Vice President and Chief Financial Officer 58 未披露 未持股 2026-05-15
James Winters Corporate Vice President, Manufacturing and Supply Chain 53 140.91万美元 1.76 2026-05-15
Daniel V. Logue Corporate Vice President, General Counsel and Secretary 52 未披露 2.70 2026-05-15
Stuart A. Randle Chief Executive Officer and Director and Interim President 67 28.33万美元 1.54 2026-05-15

董事简历

中英对照 |  中文 |  英文
Candace H. Duncan

Candace H. Duncan,自2015年起担任Teleflex董事,目前担任审计委员会主席。她在KPMG LLP(一家公共会计公司)工作了35年,于2013年11月退休。从2009年到退休,她是KPMG's Washington的管理合伙人,并担任KPMG董事会成员。早些时候,她曾在KPMG担任各种职务,包括负责大西洋中部地区审计的管理合伙人和负责KPMG弗吉尼亚州业务部门的审计合伙人。她目前是Discover Financial Services的董事。


Candace H. Duncan has been a director of Teleflex since 2015 and currently serves as chair of the Audit Committee and a member of the Nominating and Governance Committee. Ms. Duncan retired in November 2013 after a 35 year career with KPMG LLP, a public accounting firm. From 2009 until her retirement, she was the managing partner of KPMG's Washington, D.C. office and served on KPMG's board of directors. Earlier, Ms. Duncan served in various capacities at KPMG, including managing partner for audit for the Mid Atlantic area and audit partner in charge of KPMG's Virginia business unit.
Candace H. Duncan,自2015年起担任Teleflex董事,目前担任审计委员会主席。她在KPMG LLP(一家公共会计公司)工作了35年,于2013年11月退休。从2009年到退休,她是KPMG's Washington的管理合伙人,并担任KPMG董事会成员。早些时候,她曾在KPMG担任各种职务,包括负责大西洋中部地区审计的管理合伙人和负责KPMG弗吉尼亚州业务部门的审计合伙人。她目前是Discover Financial Services的董事。
Candace H. Duncan has been a director of Teleflex since 2015 and currently serves as chair of the Audit Committee and a member of the Nominating and Governance Committee. Ms. Duncan retired in November 2013 after a 35 year career with KPMG LLP, a public accounting firm. From 2009 until her retirement, she was the managing partner of KPMG's Washington, D.C. office and served on KPMG's board of directors. Earlier, Ms. Duncan served in various capacities at KPMG, including managing partner for audit for the Mid Atlantic area and audit partner in charge of KPMG's Virginia business unit.
Neena M. Patil

Neena M. Patil,于2022年8月被任命为Jazz Pharmaceuticals Public Limited公司执行副总裁兼首席法务官。Patil女士于2019年7月加入Jazz Pharmaceuticals担任高级副总裁兼总法律顾问。从2018年9月到2019年7月,Patil女士担任Abeona Therapeutics Inc.(临床阶段生物制药公司)的高级副总裁、总法律顾问兼公司秘书。在此之前,从2008年5月到2016年10月,她曾担任Novo Nordisk Inc.的管理职位,最终担任法律事务副总裁和助理总法律顾问。2008年之前,她曾任职于其他几家全球生物制药公司,包括辉瑞、GPC Biotech和赛诺菲。她担任Teleflex, Inc.(全球医疗技术提供商)的董事会成员。她还担任在非洲运营的全球医疗保健组织U.S. Board of Mothers 2 Mothers的成员。她持有Georgetown University学士学位和密歇根大学卫生服务管理法学博士和硕士学位。


Neena M. Patil has been a director of Teleflex since 2022 and currently serves as a member of the Nominating and Governance Committee. Since February 2021, she has held the position of Chief Legal Officer and Executive Vice President of Jazz Pharmaceuticals plc, a biopharmaceutical company. From July 2019 to February 2021, Ms. Patil served as Senior Vice President and General Counsel of Jazz Pharmaceuticals. Prior to joining Jazz Pharmaceuticals, Ms. Patil was Senior Vice President, General Counsel and Corporate Secretary of Abeona Therapeutics Inc., a clinical stage biopharmaceutical company, from September 2018 to July 2019. Prior to that, from May 2008 to October 2016, Ms. Patil served in various management positions at Novo Nordisk Inc., culminating in her role as Vice President for Legal Affairs and Associate General Counsel. Prior to 2008, she worked for several other global biopharmaceutical companies including Pfizer Inc., GPC Biotech AG and Sanofi.
Neena M. Patil,于2022年8月被任命为Jazz Pharmaceuticals Public Limited公司执行副总裁兼首席法务官。Patil女士于2019年7月加入Jazz Pharmaceuticals担任高级副总裁兼总法律顾问。从2018年9月到2019年7月,Patil女士担任Abeona Therapeutics Inc.(临床阶段生物制药公司)的高级副总裁、总法律顾问兼公司秘书。在此之前,从2008年5月到2016年10月,她曾担任Novo Nordisk Inc.的管理职位,最终担任法律事务副总裁和助理总法律顾问。2008年之前,她曾任职于其他几家全球生物制药公司,包括辉瑞、GPC Biotech和赛诺菲。她担任Teleflex, Inc.(全球医疗技术提供商)的董事会成员。她还担任在非洲运营的全球医疗保健组织U.S. Board of Mothers 2 Mothers的成员。她持有Georgetown University学士学位和密歇根大学卫生服务管理法学博士和硕士学位。
Neena M. Patil has been a director of Teleflex since 2022 and currently serves as a member of the Nominating and Governance Committee. Since February 2021, she has held the position of Chief Legal Officer and Executive Vice President of Jazz Pharmaceuticals plc, a biopharmaceutical company. From July 2019 to February 2021, Ms. Patil served as Senior Vice President and General Counsel of Jazz Pharmaceuticals. Prior to joining Jazz Pharmaceuticals, Ms. Patil was Senior Vice President, General Counsel and Corporate Secretary of Abeona Therapeutics Inc., a clinical stage biopharmaceutical company, from September 2018 to July 2019. Prior to that, from May 2008 to October 2016, Ms. Patil served in various management positions at Novo Nordisk Inc., culminating in her role as Vice President for Legal Affairs and Associate General Counsel. Prior to 2008, she worked for several other global biopharmaceutical companies including Pfizer Inc., GPC Biotech AG and Sanofi.
Jaewon Ryu

Jaewon Ryu自2023年起担任泰利福的董事,目前担任薪酬委员会成员。自2024年4月以来,Ryu博士一直担任Risant Health的首席执行官,Risant Health是一家非营利性医疗保健组织,为其成员健康系统提供支持系统和服务。2019年6月至2024年4月,Ryu博士担任歌辛格健康的总裁兼首席执行官,该公司是一家集临床企业、健康计划、医学院和研创功能于一体的医疗保健系统。他于2016年10月加入盖辛格,担任执行副总裁兼首席医疗官至2018年12月。2018年12月至2019年6月,任歌辛格临时总裁兼首席执行官。在加入歌辛格之前,Ryu博士于2014年1月至2016年9月期间担任健康保险公司哈门那,公司的总裁,Integrated Care Delivery。在此之前,他曾在伊利诺伊大学医院和Health Sciences系统以及Kaiser Permanente担任过各种领导职务,此前曾担任企业医疗保健律师,并曾在医疗保险和医疗补助服务中心以及退伍军人事务部担任政府职务。Ryu博士现任Privia Health Group, Inc.董事


Jaewon Ryu has been a director of Teleflex since 2023 and currently serves as a member of the Compensation Committee. Since April 2024, Dr. Ryu has been the Chief Executive Officer of Risant Health, a nonprofit healthcare organization that provides support systems and services to its constituent health systems. From June 2019 to April 2024, Dr. Ryu served as the President and Chief Executive Officer of Geisinger Health, an integrated healthcare system with a clinical enterprise, health plan, a school of medicine and research and innovation functions. He joined Geisinger in October 2016 and served as Executive Vice President and Chief Medical Officer until December 2018. From December 2018 to June 2019, he served as Interim President and Chief Executive Officer of Geisinger. Prior to joining Geisinger, Dr. Ryu served as President, Integrated Care Delivery for Humana, Inc., a health insurance company, from January 2014 to September 2016. Previously, he served in various leadership capacities at the University of Illinois Hospital and Health Sciences System and Kaiser Permanente, after having practiced as a corporate healthcare attorney and worked in government roles at the Centers for Medicare and Medicaid Services and the Department of Veterans Affairs. Dr. Ryu is currently a director of Privia Health Group, Inc.
Jaewon Ryu自2023年起担任泰利福的董事,目前担任薪酬委员会成员。自2024年4月以来,Ryu博士一直担任Risant Health的首席执行官,Risant Health是一家非营利性医疗保健组织,为其成员健康系统提供支持系统和服务。2019年6月至2024年4月,Ryu博士担任歌辛格健康的总裁兼首席执行官,该公司是一家集临床企业、健康计划、医学院和研创功能于一体的医疗保健系统。他于2016年10月加入盖辛格,担任执行副总裁兼首席医疗官至2018年12月。2018年12月至2019年6月,任歌辛格临时总裁兼首席执行官。在加入歌辛格之前,Ryu博士于2014年1月至2016年9月期间担任健康保险公司哈门那,公司的总裁,Integrated Care Delivery。在此之前,他曾在伊利诺伊大学医院和Health Sciences系统以及Kaiser Permanente担任过各种领导职务,此前曾担任企业医疗保健律师,并曾在医疗保险和医疗补助服务中心以及退伍军人事务部担任政府职务。Ryu博士现任Privia Health Group, Inc.董事
Jaewon Ryu has been a director of Teleflex since 2023 and currently serves as a member of the Compensation Committee. Since April 2024, Dr. Ryu has been the Chief Executive Officer of Risant Health, a nonprofit healthcare organization that provides support systems and services to its constituent health systems. From June 2019 to April 2024, Dr. Ryu served as the President and Chief Executive Officer of Geisinger Health, an integrated healthcare system with a clinical enterprise, health plan, a school of medicine and research and innovation functions. He joined Geisinger in October 2016 and served as Executive Vice President and Chief Medical Officer until December 2018. From December 2018 to June 2019, he served as Interim President and Chief Executive Officer of Geisinger. Prior to joining Geisinger, Dr. Ryu served as President, Integrated Care Delivery for Humana, Inc., a health insurance company, from January 2014 to September 2016. Previously, he served in various leadership capacities at the University of Illinois Hospital and Health Sciences System and Kaiser Permanente, after having practiced as a corporate healthcare attorney and worked in government roles at the Centers for Medicare and Medicaid Services and the Department of Veterans Affairs. Dr. Ryu is currently a director of Privia Health Group, Inc.
Stuart A. Randle

Stuart A. Randle,自2009年以来,他一直担任泰利福公司的董事,目前作为薪酬委员会的成员。先生自2004年2月以来,他担任GI Dynamics公司的总裁兼首席执行官,这是一家医疗设备公司。从2003年到2004年,他担任Optobionics公司的临时首席执行官。从2002年到2003年,他担任先进技术企业的企业家,一家医疗和风险资本公司。从1998年到2001年,他担任Act Medical的总裁兼首席执行官,1998年之前Randle先生担任忠诚医疗公司高级管理职位和巴克斯特国际公司的高管职位。Randle先生目前担任Beacon Roofing Supply公司的董事成员和先进医疗技术协会的董事会成员。


Stuart A. Randle has been a director of Teleflex since 2009. He became Teleflex Incorporated's Interim President and Chief Executive Officer on January 8, 2026. In December 2018, Mr. Randle retired after serving for three years as the Chief Executive Officer of Ivenix, Inc., a medical device company that provides infusion delivery systems. Previously, Mr. Randle had been retired since September 2014 after serving for 10 years as President and Chief Executive Officer of GI Dynamics, Inc., a medical device company. From 2003 to 2004, he served as Interim Chief Executive Officer of Optobionics Corporation, a medical device company. From 2002 to 2003, Mr. Randle held the position of Entrepreneur in Residence of Advanced Technology Ventures, a healthcare and information technology venture capital firm. From 1998 to 2001, he was President and Chief Executive Officer of Act Medical, Inc. Prior to 1998, Mr. Randle held various senior management positions with Allegiance Healthcare Corporation and Baxter International Inc.
Stuart A. Randle,自2009年以来,他一直担任泰利福公司的董事,目前作为薪酬委员会的成员。先生自2004年2月以来,他担任GI Dynamics公司的总裁兼首席执行官,这是一家医疗设备公司。从2003年到2004年,他担任Optobionics公司的临时首席执行官。从2002年到2003年,他担任先进技术企业的企业家,一家医疗和风险资本公司。从1998年到2001年,他担任Act Medical的总裁兼首席执行官,1998年之前Randle先生担任忠诚医疗公司高级管理职位和巴克斯特国际公司的高管职位。Randle先生目前担任Beacon Roofing Supply公司的董事成员和先进医疗技术协会的董事会成员。
Stuart A. Randle has been a director of Teleflex since 2009. He became Teleflex Incorporated's Interim President and Chief Executive Officer on January 8, 2026. In December 2018, Mr. Randle retired after serving for three years as the Chief Executive Officer of Ivenix, Inc., a medical device company that provides infusion delivery systems. Previously, Mr. Randle had been retired since September 2014 after serving for 10 years as President and Chief Executive Officer of GI Dynamics, Inc., a medical device company. From 2003 to 2004, he served as Interim Chief Executive Officer of Optobionics Corporation, a medical device company. From 2002 to 2003, Mr. Randle held the position of Entrepreneur in Residence of Advanced Technology Ventures, a healthcare and information technology venture capital firm. From 1998 to 2001, he was President and Chief Executive Officer of Act Medical, Inc. Prior to 1998, Mr. Randle held various senior management positions with Allegiance Healthcare Corporation and Baxter International Inc.
Andrew A. Krakauer

Andrew A. Krakauer自2018年起担任Teleflex董事,目前担任薪酬委员会成员。在2016年10月退休之前,Krakauer先生是Cantel Medical Corp.“Cantel”的首席执行官,Cantel Medical Corp.是一家感染控制产品和服务供应商。在Cantel工作的12年间,Krakauer先生担任过多个行政和高级职位,包括2014年11月至2016年7月担任首席执行官;2009年3月至2014年11月担任总裁兼首席执行官;2008年4月至2009年3月担任总裁;2004年8月至2008年4月担任执行副总裁兼首席运营官。2009年至2016年,Krakauer还担任Cantel董事会成员。在加入Cantel之前,Krakauer先生于1998年至2004年担任医疗设备供应商Instrumentarium Corp.(Instrumentarium Corp.于2003年被General Electric Company收购)Ohmeda医疗部的总裁。Krakauer先生目前担任KL Acquisition公司董事。


Andrew A. Krakauer has been a director of Teleflex since 2018 and currently serves as chair of the Compensation Committee. Prior to his retirement in October 2016, Mr. Krakauer was Chief Executive Officer of Cantel Medical Corp. ("Cantel"), a provider of infection control products and services. During his 12 years at Cantel, Mr. Krakauer served in various executive positions, including Chief Executive Officer from November 2014 to July 2016; President and Chief Executive Officer from March 2009 to November 2014; President from April 2008 to March 2009; and Executive Vice President and Chief Operating Officer from August 2004 through April 2008. Mr. Krakauer also served as a member of Cantel's board of directors from 2009 to 2016. Prior to joining Cantel, Mr. Krakauer was President of the Ohmeda Medical Division of Instrumentarium Corp. (which was acquired by General Electric Company in 2003), a provider of medical devices, from 1998 to 2004.
Andrew A. Krakauer自2018年起担任Teleflex董事,目前担任薪酬委员会成员。在2016年10月退休之前,Krakauer先生是Cantel Medical Corp.“Cantel”的首席执行官,Cantel Medical Corp.是一家感染控制产品和服务供应商。在Cantel工作的12年间,Krakauer先生担任过多个行政和高级职位,包括2014年11月至2016年7月担任首席执行官;2009年3月至2014年11月担任总裁兼首席执行官;2008年4月至2009年3月担任总裁;2004年8月至2008年4月担任执行副总裁兼首席运营官。2009年至2016年,Krakauer还担任Cantel董事会成员。在加入Cantel之前,Krakauer先生于1998年至2004年担任医疗设备供应商Instrumentarium Corp.(Instrumentarium Corp.于2003年被General Electric Company收购)Ohmeda医疗部的总裁。Krakauer先生目前担任KL Acquisition公司董事。
Andrew A. Krakauer has been a director of Teleflex since 2018 and currently serves as chair of the Compensation Committee. Prior to his retirement in October 2016, Mr. Krakauer was Chief Executive Officer of Cantel Medical Corp. ("Cantel"), a provider of infection control products and services. During his 12 years at Cantel, Mr. Krakauer served in various executive positions, including Chief Executive Officer from November 2014 to July 2016; President and Chief Executive Officer from March 2009 to November 2014; President from April 2008 to March 2009; and Executive Vice President and Chief Operating Officer from August 2004 through April 2008. Mr. Krakauer also served as a member of Cantel's board of directors from 2009 to 2016. Prior to joining Cantel, Mr. Krakauer was President of the Ohmeda Medical Division of Instrumentarium Corp. (which was acquired by General Electric Company in 2003), a provider of medical devices, from 1998 to 2004.
Michael J. Tokich

Michael J. Tokich自2014年2月起担任高级副总裁、首席财务官兼财务主管。2008年3月至2014年2月他曾任高级副总裁兼首席财务官。


Michael J. Tokich has been a director since February 2026. He serves on the Audit Committee. Since Augt 2025, Mr. Tokich serves as the Senior Financial Advisor at STERIS plc, a leading global healthcare and life science provider of products and services. Prior to his current role, Mr. Tokich most recently served STERIS as Senior Vice President and Chief Financial Officer. Mr. Tokich joined STERIS in 2000 and held vario senior financial roles prior to his appointment as CFO in 2008.
Michael J. Tokich自2014年2月起担任高级副总裁、首席财务官兼财务主管。2008年3月至2014年2月他曾任高级副总裁兼首席财务官。
Michael J. Tokich has been a director since February 2026. He serves on the Audit Committee. Since Augt 2025, Mr. Tokich serves as the Senior Financial Advisor at STERIS plc, a leading global healthcare and life science provider of products and services. Prior to his current role, Mr. Tokich most recently served STERIS as Senior Vice President and Chief Financial Officer. Mr. Tokich joined STERIS in 2000 and held vario senior financial roles prior to his appointment as CFO in 2008.
Gretchen R. Haggerty

Gretchen R. Haggerty曾在全球一体化钢铁生产商美国钢铁公司及其前身X公司工作了37年。曾担任执行副总裁兼首席财务官,并于2003年3月至退休期间担任美国钢铁和卡内基养老基金及其投资委员会主席。曾在美国钢铁和X公司担任多个财务主管职务,从1991年11月开始担任副总裁兼财务主管。目前担任医疗技术产品和ATM过滤技术的全球供应商泰利福 Corporation的董事,为公路商用车辆和非公路农业、建筑、采矿和por生成车辆和设备提供过滤产品的领先供应商。


Gretchen R. Haggerty has been a director of Teleflex since 2016 and currently serves as a member of the Audit Committee. Ms. Haggerty retired in August 2013 after a 37 year career with United States Steel Corporation, an integrated global steel producer, and its predecessor, USX Corporation, which, in addition to its steel production, also conducted energy operations, principally through Marathon Oil Corporation. From March 2003 until her retirement, she served as Executive Vice President & Chief Financial Officer and also served as Chairman of the U.S. Steel & Carnegie Pension Fund and its Investment Committee. Earlier, she served in various financial executive positions at U.S. Steel and USX, beginning in November 1991 when she became Vice President & Treasurer. Ms. Haggerty is currently a director of Atmus Filtration Technologies Inc. and Johnson Controls International plc.
Gretchen R. Haggerty曾在全球一体化钢铁生产商美国钢铁公司及其前身X公司工作了37年。曾担任执行副总裁兼首席财务官,并于2003年3月至退休期间担任美国钢铁和卡内基养老基金及其投资委员会主席。曾在美国钢铁和X公司担任多个财务主管职务,从1991年11月开始担任副总裁兼财务主管。目前担任医疗技术产品和ATM过滤技术的全球供应商泰利福 Corporation的董事,为公路商用车辆和非公路农业、建筑、采矿和por生成车辆和设备提供过滤产品的领先供应商。
Gretchen R. Haggerty has been a director of Teleflex since 2016 and currently serves as a member of the Audit Committee. Ms. Haggerty retired in August 2013 after a 37 year career with United States Steel Corporation, an integrated global steel producer, and its predecessor, USX Corporation, which, in addition to its steel production, also conducted energy operations, principally through Marathon Oil Corporation. From March 2003 until her retirement, she served as Executive Vice President & Chief Financial Officer and also served as Chairman of the U.S. Steel & Carnegie Pension Fund and its Investment Committee. Earlier, she served in various financial executive positions at U.S. Steel and USX, beginning in November 1991 when she became Vice President & Treasurer. Ms. Haggerty is currently a director of Atmus Filtration Technologies Inc. and Johnson Controls International plc.

高管简历

中英对照 |  中文 |  英文
Cameron P. Hicks

Cameron P. Hicks2013年4月起担任Teleflex Incorporated公司人力资源和通信副总裁。加入Teleflex之前,2010年7月至2013年3月,他担任Harlan Laboratories, Inc.(临床前和非临床研究服务的私人全球供应商)的人力资源和组织有效性执行副总裁。1990年4月至2010年1月,他在MDS公司担任各种领导职务,MDS公司是药物开发和疾病诊断和治疗的产品和服务提供商,包括2000年11月至2010年1月MDS全球制药服务部门的人力资源高级副总裁。


Cameron P. Hicks,has been Corporate Vice President, Human Resources and Communications since April 2013. Prior to joining Teleflex, Mr. Hicks served as Executive Vice President of Human Resources & Organizational Effectiveness for Harlan Laboratories, Inc., a private global provider of pre-clinical and non-clinical research services, from July 2010 to March 2013. From April 1990 to January 2010, Mr. Hicks held various leadership roles with MDS Inc., a provider of products and services for the development of drugs and the diagnosis and treatment of disease, including Senior Vice President of Human Resources for MDS' global Pharma Services division from November 2000 to January 2010.
Cameron P. Hicks2013年4月起担任Teleflex Incorporated公司人力资源和通信副总裁。加入Teleflex之前,2010年7月至2013年3月,他担任Harlan Laboratories, Inc.(临床前和非临床研究服务的私人全球供应商)的人力资源和组织有效性执行副总裁。1990年4月至2010年1月,他在MDS公司担任各种领导职务,MDS公司是药物开发和疾病诊断和治疗的产品和服务提供商,包括2000年11月至2010年1月MDS全球制药服务部门的人力资源高级副总裁。
Cameron P. Hicks,has been Corporate Vice President, Human Resources and Communications since April 2013. Prior to joining Teleflex, Mr. Hicks served as Executive Vice President of Human Resources & Organizational Effectiveness for Harlan Laboratories, Inc., a private global provider of pre-clinical and non-clinical research services, from July 2010 to March 2013. From April 1990 to January 2010, Mr. Hicks held various leadership roles with MDS Inc., a provider of products and services for the development of drugs and the diagnosis and treatment of disease, including Senior Vice President of Human Resources for MDS' global Pharma Services division from November 2000 to January 2010.
John R. Deren

自2013年加入公司以来,John R. Deren在泰利福财务组织内承担了广泛的职责。在任职期间,John曾担任财务部门多项职能的执行监督,包括企业融资、财务共享服务、全球供应链金融、财务和税务。他的职业生涯始于罗兵咸永道会计师事务所,并在罗门哈斯会计师事务所获得注册会计师,之后在加入泰利福之前在罗门哈斯、爱克斯龙一代和Trinseo担任财务领导职务。


John R. Deren,has been Executive Vice President and Chief Financial Officer since April 2025. From August 2021 to March 2025, Mr. Deren was Teleflex Incorporated Corporate Vice President and Chief Accounting Officer and from May 2017 to August 2021, he was Teleflex Incorporated Vice President and Chief Accounting Officer. He joined Teleflex in May 2013 as Vice President, Finance and Corporate Controller. Prior to joining Teleflex, Mr. Deren served as Vice President and Global Controller of Trinseo PLC (formerly known as Styron LLC), a global specialty materials company, from January 2011 until April 2013. Mr. Deren has also held leadership positions with Exelon Generation, Rohm and Haas Company, and began his career at PricewaterhouseCoopers where he held positions of increasing responsibility through Senior Manager.
自2013年加入公司以来,John R. Deren在泰利福财务组织内承担了广泛的职责。在任职期间,John曾担任财务部门多项职能的执行监督,包括企业融资、财务共享服务、全球供应链金融、财务和税务。他的职业生涯始于罗兵咸永道会计师事务所,并在罗门哈斯会计师事务所获得注册会计师,之后在加入泰利福之前在罗门哈斯、爱克斯龙一代和Trinseo担任财务领导职务。
John R. Deren,has been Executive Vice President and Chief Financial Officer since April 2025. From August 2021 to March 2025, Mr. Deren was Teleflex Incorporated Corporate Vice President and Chief Accounting Officer and from May 2017 to August 2021, he was Teleflex Incorporated Vice President and Chief Accounting Officer. He joined Teleflex in May 2013 as Vice President, Finance and Corporate Controller. Prior to joining Teleflex, Mr. Deren served as Vice President and Global Controller of Trinseo PLC (formerly known as Styron LLC), a global specialty materials company, from January 2011 until April 2013. Mr. Deren has also held leadership positions with Exelon Generation, Rohm and Haas Company, and began his career at PricewaterhouseCoopers where he held positions of increasing responsibility through Senior Manager.
James Winters

James Winters,自2020年2月起担任Teleflex Incorporated制造和供应链副总裁。他曾于2018年3月至2020年1月担任全球制造副总裁。在加入Teleflex之前,Winters先生于2005年8月至2018年2月在医疗保健公司DePuy Synthes部门担任过多个高级管理和运营职务。最近,Winters先生于2015年2月至2018年2月担任DePuy Synthes全球联合重组全球制造副总裁。在此之前,Winters先生担任DePuy Synthes爱尔兰制造业务的工厂经理。


James Winters,has been Corporate Vice President, Manufacturing and Supply Chain since February 2020. He previously held the position of Vice President, Global Manufacturing from March 2018 to January 2020. Prior to joining Teleflex, Mr. Winters held various senior management and operational roles with the DePuy Synthes division of Johnson & Johnson, a healthcare company, from August 2005 to February 2018. Most recently, Mr. Winters served as Vice President of Global Manufacturing for Global Joint Reconstruction for DePuy Synthes from February 2015 to February 2018. Prior to that, Mr. Winters served as Plant Manager for the DePuy Synthes Ireland Manufacturing Operation.
James Winters,自2020年2月起担任Teleflex Incorporated制造和供应链副总裁。他曾于2018年3月至2020年1月担任全球制造副总裁。在加入Teleflex之前,Winters先生于2005年8月至2018年2月在医疗保健公司DePuy Synthes部门担任过多个高级管理和运营职务。最近,Winters先生于2015年2月至2018年2月担任DePuy Synthes全球联合重组全球制造副总裁。在此之前,Winters先生担任DePuy Synthes爱尔兰制造业务的工厂经理。
James Winters,has been Corporate Vice President, Manufacturing and Supply Chain since February 2020. He previously held the position of Vice President, Global Manufacturing from March 2018 to January 2020. Prior to joining Teleflex, Mr. Winters held various senior management and operational roles with the DePuy Synthes division of Johnson & Johnson, a healthcare company, from August 2005 to February 2018. Most recently, Mr. Winters served as Vice President of Global Manufacturing for Global Joint Reconstruction for DePuy Synthes from February 2015 to February 2018. Prior to that, Mr. Winters served as Plant Manager for the DePuy Synthes Ireland Manufacturing Operation.
Daniel V. Logue

Daniel V. Logue,他一直担任Teleflex Incorporated副总裁、总法律顾问和秘书(2021年1月以来)。Logue先生于2004年加入Teleflex,此前曾担任副总法律顾问(2017年2月至2020年12月),副总法律顾问(2013年3月至2017年1月),助理总法律顾问(2004年6月至2013年2月)。加入Teleflex之前,1999年9月至2004年6月,Logue先生是律师事务所Pepper Hamilton LLP(现为Troutman Pepper Hamilton Sanders LLP)的助理。


Daniel V. Logue,has been Corporate Vice President, General Counsel and Secretary since January 2021. Mr. Logue joined Teleflex in 2004 and previously held the positions of Deputy General Counsel from February 2017 to December 2020, Associate General Counsel from March 2013 to January 2017 and Assistant General Counsel from June 2004 to February 2013. Prior to joining Teleflex, Mr. Logue was an associate at the law firm of Pepper Hamilton LLP (now Troutman Pepper Locke LLP) from September 1999 to June 2004.
Daniel V. Logue,他一直担任Teleflex Incorporated副总裁、总法律顾问和秘书(2021年1月以来)。Logue先生于2004年加入Teleflex,此前曾担任副总法律顾问(2017年2月至2020年12月),副总法律顾问(2013年3月至2017年1月),助理总法律顾问(2004年6月至2013年2月)。加入Teleflex之前,1999年9月至2004年6月,Logue先生是律师事务所Pepper Hamilton LLP(现为Troutman Pepper Hamilton Sanders LLP)的助理。
Daniel V. Logue,has been Corporate Vice President, General Counsel and Secretary since January 2021. Mr. Logue joined Teleflex in 2004 and previously held the positions of Deputy General Counsel from February 2017 to December 2020, Associate General Counsel from March 2013 to January 2017 and Assistant General Counsel from June 2004 to February 2013. Prior to joining Teleflex, Mr. Logue was an associate at the law firm of Pepper Hamilton LLP (now Troutman Pepper Locke LLP) from September 1999 to June 2004.
Stuart A. Randle

Stuart A. Randle,自2009年以来,他一直担任泰利福公司的董事,目前作为薪酬委员会的成员。先生自2004年2月以来,他担任GI Dynamics公司的总裁兼首席执行官,这是一家医疗设备公司。从2003年到2004年,他担任Optobionics公司的临时首席执行官。从2002年到2003年,他担任先进技术企业的企业家,一家医疗和风险资本公司。从1998年到2001年,他担任Act Medical的总裁兼首席执行官,1998年之前Randle先生担任忠诚医疗公司高级管理职位和巴克斯特国际公司的高管职位。Randle先生目前担任Beacon Roofing Supply公司的董事成员和先进医疗技术协会的董事会成员。


Stuart A. Randle has been a director of Teleflex since 2009. He became Teleflex Incorporated's Interim President and Chief Executive Officer on January 8, 2026. In December 2018, Mr. Randle retired after serving for three years as the Chief Executive Officer of Ivenix, Inc., a medical device company that provides infusion delivery systems. Previously, Mr. Randle had been retired since September 2014 after serving for 10 years as President and Chief Executive Officer of GI Dynamics, Inc., a medical device company. From 2003 to 2004, he served as Interim Chief Executive Officer of Optobionics Corporation, a medical device company. From 2002 to 2003, Mr. Randle held the position of Entrepreneur in Residence of Advanced Technology Ventures, a healthcare and information technology venture capital firm. From 1998 to 2001, he was President and Chief Executive Officer of Act Medical, Inc. Prior to 1998, Mr. Randle held various senior management positions with Allegiance Healthcare Corporation and Baxter International Inc.
Stuart A. Randle,自2009年以来,他一直担任泰利福公司的董事,目前作为薪酬委员会的成员。先生自2004年2月以来,他担任GI Dynamics公司的总裁兼首席执行官,这是一家医疗设备公司。从2003年到2004年,他担任Optobionics公司的临时首席执行官。从2002年到2003年,他担任先进技术企业的企业家,一家医疗和风险资本公司。从1998年到2001年,他担任Act Medical的总裁兼首席执行官,1998年之前Randle先生担任忠诚医疗公司高级管理职位和巴克斯特国际公司的高管职位。Randle先生目前担任Beacon Roofing Supply公司的董事成员和先进医疗技术协会的董事会成员。
Stuart A. Randle has been a director of Teleflex since 2009. He became Teleflex Incorporated's Interim President and Chief Executive Officer on January 8, 2026. In December 2018, Mr. Randle retired after serving for three years as the Chief Executive Officer of Ivenix, Inc., a medical device company that provides infusion delivery systems. Previously, Mr. Randle had been retired since September 2014 after serving for 10 years as President and Chief Executive Officer of GI Dynamics, Inc., a medical device company. From 2003 to 2004, he served as Interim Chief Executive Officer of Optobionics Corporation, a medical device company. From 2002 to 2003, Mr. Randle held the position of Entrepreneur in Residence of Advanced Technology Ventures, a healthcare and information technology venture capital firm. From 1998 to 2001, he was President and Chief Executive Officer of Act Medical, Inc. Prior to 1998, Mr. Randle held various senior management positions with Allegiance Healthcare Corporation and Baxter International Inc.